Antibody, linker-payload, conjugation and analytics – we provide a one-stop solution for ADC discovery and development.
We understand the dynamic nature of the current ADC technology landscape and the complexities associated with it. Our team is well versed with a wide range of ADC technologies and is capable of adapting new technologies to support our client needs. We also provide expertise to develop novel liker technologies and cytotoxic payload optimization.
We offer a wide range of ADC services, and our team is competent at adapting new technologies to meet client requirements.
We offer services for designing and synthesizing ADC linkers and linker-drug conjugates. Based on the drug release mechanism, we design & synthesize different ADC linkers: Cleavable and non-cleavable linkers, self-immolation tracer-free linkers, and peptide linkers.
Our team carries out ADC conjugation services to accelerate the production of ADC constructs with quality attributes.
Amine (Lys) conjugation, thiol (Cys) conjugation, site-specific conjugation, enzymatic conjugation, glycoconjugation and click chemistry.
According to clients’ requirements, we optimize payloads such as cytotoxic, non-cytotoxic, and biological payloads. Our team handles a wide range of cytotoxic payloads, including:
Our ADC discovery programs are customized as per the target biology and desired mechanism of action. Specific screening strategies are designed and employed at a stage as early as antibody generation. Some of the early stage activities include screening and design of mAbs for internalization (or lack of it), effector function, off-site localization and half-life.
Rapid and comprehensive scouting of the linker-payload technology space can be plugged-in to identify the most desirable combinations of mAb, linker-payload and conjugation strategies. Stage appropriate in vitro screening and detailed evaluation of lead ADC molecules is carried out using customized assay platforms.
We also provide in vivo therapeutic evaluation, PK, and rodent toxicology assessment support for ADC candidates with appropriate bioanalytical methods customized for each program. Conjugation and purification process development takes into account each component of the ADC molecule. Quality, scalability, safety and cost-effectiveness concerns are addressed at each stage of process development.
A biomolecule is complex as an ADC and demands analytical assessment to ensure safety and quality. Routinely determined attributes during ADC analysis are
Site-specific conjugation technology
In-house linker library and Payload
Collaborative and solution driven
Analytical assessment to ensure safety and quality
Various commercial and customized linkers
JULY 02, 2021
Oligonucleotides as a therapeutic class is a revolutionary approach to discover new and important therapeutic agents for treating human diseases. RNA-based intervention at times works in cases where other modalities do not work. For example, it may help in treating inborn errors in metabolism, genetic disorders and rareOligonucleotide therapeutics is the use of c...
Read MoreThe global Highly Potent Active Pharmaceutical Ingredients (HPAPI) market is expected to reach USD 26.84 Billion by 2023 from USD 17.72 Billion in 2018, at a CAGR 8.7%....
Read MoreProject Challenge: Existing formulation (lower strength - 50 mg) was manufactured using direct compression process. This formulation posed poor powder flow and content uniformity issues during scale-up. Development of new strength 150 mg without any process issues was a challenge. Solution design: Preliminary pre-formulation, stress study and PSD impact assessmen...
Read More2016
A convenient and one-pot synthesis of tetracyclic isoindolo [1,2-a]quinazoline derivatives via Lewis acid mediated sequential C–N bond formation reactions is reported. This protocol provides a simple and rapid strategy for the synthesis of 12-benzylidene-10,12-dihydroisoindolo[1,2-b]quinazoline derivatives. However, a variety of tetracyclo indole fused quinazol...
Read More2005
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...
Read More2005
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...
Read More2005
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...
Read MoreYou are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.